Contineum Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 106.28K shares.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 66.25K shares, a 289.72% increase year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 4.15K shares, a 95.87% decline year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 21.51K shares, a 68.02% increase year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 42.65K shares, a 72.85% decline from fiscal 2024.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 157.09K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 106.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 198.18K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 66.25K shares 10-Q · filed 2026-05-05 | 91.91K shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 4.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 42.65K shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 21.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | 138.98K shares derived: sum of 4 quarters · filed 2025-10-30 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 130.28K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 17.00K shares 10-Q · filed 2025-05-14 | 139.21K shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 100.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 157.09K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 12.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | |
| 2024-06-30 | 8.93K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | |
| 2024-03-31 | 34.88K shares 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |